IDEXX Laboratories (IDXX) Financial History
Review IDEXX Laboratories annual and quarterly financial results, key ratios, insider transactions and SEC filing history in one chronological view. Data available from FY2008 through FY2025.
Financials
18 fiscal years, FY2008 to FY2025
Insider trades
495 trades
Risk factor changes
54 changes in the latest 10-K
Filings
Annual and quarterly reports
Compare
Side by side with another company
IDEXX Laboratories Financial Statements
History since FY2008. Annual, in US dollars. Source: 10-K XBRL data.
IDEXX Laboratories Revenue and Growth
Compare reported revenue and year-over-year revenue growth across available fiscal years.
IDEXX Laboratories Income Statements
Review revenue, gross profit, operating income, net income and earnings per share.
IDEXX Laboratories Balance Sheets
Review reported debt and book-value-based ratios where company data is available.
IDEXX Laboratories Cash Flow Statements
Compare reported free cash flow across the available fiscal history.
IDEXX Laboratories Financial Ratios
Compare net margin, price-to-earnings and price-to-book ratios by fiscal year.
| Fiscal year | FY2008 🔒 | FY2009 🔒 | FY2010 🔒 | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Revenue growth | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | — | +4.7% | +8.7% | +6.5% | +10.4% |
| Gross profit | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $1.9B | $2.0B | $2.2B | $2.4B | $2.7B |
| Operating income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.9B | $0.9B | $1.1B | $1.1B | $1.4B |
| Net income | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.7B | $0.7B | $0.8B | $0.9B | $1.1B |
| Debt | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.9B | $1.3B | $0.9B | $0.9B | $0.8B |
| Free cash flow | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $0.6B | $0.4B | $0.8B | $0.8B | $1.1B |
| Net margin | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 23.2% | 20.2% | 23.1% | 22.8% | 24.6% |
| EPS (diluted) | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| P/E ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 76.6× | 50.8× | 55.2× | 38.8× | 51.7× |
| P/B ratio | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | 80.7× | 55.5× | 31.1× | 21.2× | 33.6× |
Daily closing prices, aggregated by calendar year.
| Year | 2000 🔒 | 2001 🔒 | 2002 🔒 | 2003 🔒 | 2004 🔒 | 2005 🔒 | 2006 🔒 | 2007 🔒 | 2008 🔒 | 2009 🔒 | 2010 🔒 | 2011 🔒 | 2012 🔒 | 2013 🔒 | 2014 🔒 | 2015 🔒 | 2016 🔒 | 2017 🔒 | 2018 🔒 | 2019 🔒 | 2020 🔒 | 2021 🔒 | 2022 | 2023 | 2024 | 2025 | 2026 (YTD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Open | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $656.11 | $411.10 | $548.39 | $415.00 | $676.91 |
| Close | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $407.85 | $555.31 | $413.58 | $676.64 | $669.84 |
| High | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $657.68 | $567.74 | $583.02 | $769.08 | $727.43 |
| Low | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $317.10 | $372.51 | $400.02 | $356.25 | $500.93 |
| Annual return | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | -38.1% | +36.2% | -25.5% | +63.6% | -1.0% |
IDEXX Laboratories Insider Transactions
From Form 4 filings. Showing the latest 5 of 495 trades.
| Traded | Filed | Insider | Type | Shares | Value | % of holdings |
|---|---|---|---|---|---|---|
| 2026-11-04 | 2026-11-05 | Sharon Underberg Executive VP | Option exercise (2 trades) | 17,812 | $2.6M | — |
| 2026-11-04 | 2026-11-05 | Sharon Underberg Executive VP | Sold (3 trades) | 8,906 | $6.1M at ~$689 | 55% |
| 2026-11-04 | 2026-11-05 | Jonathan Jay Mazelsky Executive Chair of the Board | Option exercise (2 trades) | 50,280 | $4.5M | — |
| 2026-11-04 | 2026-11-05 | Jonathan Jay Mazelsky Executive Chair of the Board | Sold (13 trades) | 25,140 | $17.7M at ~$703 | 23% |
| 2026-11-04 | 2026-11-05 | Michael Lane Executive Vice President | Sold (3 trades) | 3,978.944 | $2.7M at ~$689 | 49% |
IDEXX Laboratories Risk Factor Changes
Latest 10-K compared with the year before. 54 changes found.
The trading price of our common stock may be volatile.
Borrowings under our Credit Facility bear interest at variable rates, including rates based on the Secured Overnight Financing Rate (“SOFR”), exposing us to interest rate risk.
If the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our business, results of operations and financial condition could be materially adversely affected.
Our income tax filings are subject to examination by various tax authorities, and the final determination of tax audits could be materially different from that which is reflected in historical income tax provisions an…
We operate in many regions around the world where our businesses and the activities of our customers and suppliers could be disrupted by climate change.
Our ability to achieve any of these goals is subject to numerous risks, many of which are outside of our control and depend in part on third-party performance or data, and there can be no assurance that we will achiev…
We strive to align our environmental, social and governance goals with our long-term business-strategy and Purpose.
Any failure or perceived failure by us, the third parties with whom we work, or our products and services to comply with all applicable privacy-related laws, regulations, and standards, as well as our contractual obli…
An additional area of complexity concerns the restrictions on transfers of personal data from certain countries to others.
While we maintain a program to monitor, assess, and comply with applicable global data privacy laws and relevant industry standards, compliance with these evolving requirements is costly, may require us to change our…
Our business operations involve the receipt, storage, transmission, and use of information, including personal data, about our customers, pet owners, suppliers, and employees.
We are subject to risks associated with public health issues, including pandemics and other events beyond our control.
practices.
otherwise protected information, and similar events, and will likely experience further attacks, breaches and incidents in the future, potentially with more frequency.
Our software and some of our other products and services incorporate or rely on information technology and systems that are highly technical and complex, and the timely development, testing, release and deployment of…
The loss of the services of, or our failure to recruit or develop and implement effective succession plans for, our senior leadership, other key personnel, and employees may significantly delay or prevent the achievem…
Our continued success is substantially dependent on our ability to attract, develop, and retain highly capable and skilled leaders, employees, and other key personnel.
Demand for our companion animal, livestock and poultry diagnostic tests and our dairy and water testing products could be negatively impacted by factors impacting testing practices.
which could have a negative impact on our profitability and results of operations.
Veterinarians are our primary customers for our CAG products and services, and the veterinary services industry in the U.S.
There has been a recent focus in the U.S.
assurance that confidential, proprietary information provided to foreign regulatory agencies may not be accessed by unauthorized persons or otherwise stolen, which could negatively impact our ability to protect our pr…
In addition, some foreign governments require us to register or certify our products before they can be distributed or sold, and these product registration requirements, which vary among the applicable jurisdictions a…
The manufacture, import, and sale of our products, as well as our research and development processes, are subject to similar and sometimes more stringent laws in many foreign countries.
Delays by government agencies in approving new products or product upgrades or taking action with respect to other regulatory matters could have a negative impact on our growth and profitability.
As a global business, we sell products and services in more than 175 countries and operate in an increasingly complex legal and regulatory environment.
We have built, and expect to continue to build, AI into many of our product and service offerings, and we expect this element of our business to grow.
Issues in our use of AI may result in reputational harm or liability and adversely affect our business
some contracts with suppliers we have minimum purchase obligations, and our failure to satisfy those obligations may result in loss of some or all of our rights under these contracts or require us to compensate the su…
We seek to mitigate sole and single-source supplier risks on a risk-prioritized basis and in a variety of ways, including, when possible, by identifying and qualifying alternative suppliers, developing applicable in-h…
•Strengthening our sales and marketing activities to reach customers and expand diagnostic and software use both in and outside the U.S.;
•Continuing to expand, develop, and advance the effectiveness and productivity of our companion animal diagnostic sales, marketing, customer support, and logistics organizations in the U.S.
•Achieving cost improvements in the manufacture and service of our point-of-care laboratory analyzers by employing the benefits of economies of scale in both negotiating supply contracts and leveraging manufacturing o…
•Achieving cost improvements in our worldwide reference laboratory network by implementing global best practices, including lean processing techniques, technological enhancements (e.g., automation and a global laborat…
•Developing and introducing new or improved innovative diagnostic tests and services for both our reference laboratories and point-of-care applications that provide valuable medical information to our customers and ef…
•Developing, manufacturing, and marketing innovative new or improved and cost competitive point-of-care laboratory analyzers that drive sales of IDEXX VetLab instruments, grow our installed base of instruments, and in…
The companion animal healthcare industry is highly competitive, and we anticipate increasing competition from both existing competitors and new sector entrants given our performance and the industry’s strong growth an…
Our business lines are highly attractive and highly competitive.
You should consider carefully the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K in evaluating our company and our…
The nature of our global operations subjects us to local, state, regional and federal tax laws in jurisdictions around the world.
effect on our business.
could cause a decline in demand for our products and services.
technology, market risk and reputational risk) and social and human effects (such as harm to health and well-being) associated with climate change.
that had been previously remedied or from malicious code injected in a “supply chain” cyberattack.
As information systems and the use of software and related applications by us, our business partners, suppliers, and customers become more cloud-based and connected to the “Internet of Things” (“IoT”), there has been…
We rely on our information systems, as well as third-party information systems, to provide access to our web-based products and services, keep financial records, analyze results of operations, process orders and shipm…
Our continued success is substantially dependent on our ability to attract, develop, and retain highly capable and skilled employees and leaders.
patent applications by the U.S.
The nature of our global operations subjects us to local, state, regional, and federal tax laws in jurisdictions around the world.
provider could be negatively impacted, and we may be exposed to government enforcement actions, private litigation, and increased scrutiny from investors, special interest groups, government regulators, and other stak…
A substantial percentage of our sales are made worldwide to the companion animal veterinary industry.
In addition, to market and sell many of our products outside the U.S., we are subject to product approval and registration requirements that often require us to provide confidential, proprietary information about thos…
We, and some of our third-party vendors, have experienced cybersecurity attacks by threat actors (which may include state-sponsored organizations or nation state actors) and other cybersecurity breaches and incidents…
We rely on our information systems and third-party information systems to provide access to our web-based products and services, keep financial records, analyze results of operations, process orders and shipments, man…
IDEXX Laboratories SEC Filings
Latest annual and quarterly reports, current reports, proxy statements and ownership filings.
| Form | Filed | Description | Document |
|---|---|---|---|
| Quarterly report (10-Q) | 2026-11-02 | Quarter ended Sep 30, 2026 | View document |
| Current report (8-K) | 2026-11-02 | Quarterly results | View document |
| Ownership change (13D/13G) | 2026-10-30 | Large shareholder report (5% or more) | View document |
| Quarterly report (10-Q) | 2026-08-04 | Quarter ended Jun 30, 2026 | View document |
| Current report (8-K) | 2026-08-04 | Quarterly results | View document |
IDEXX Laboratories financial metrics by year
IDEXX Laboratories in the S&P 500 rankings
- #80 by net profit margin as of FY2025
- #85 by diluted earnings per share as of FY2025
S&P 500 is a trademark of S&P Dow Jones Indices LLC. StockYears is not affiliated with or endorsed by S&P Dow Jones Indices.